HC Wainwright Comments on Gain Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:GANX)

Gain Therapeutics, Inc. (NASDAQ:GANXGet Rating) – Stock analysts at HC Wainwright lifted their FY2022 earnings per share estimates for Gain Therapeutics in a research report issued on Monday, November 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($1.41) for the year, up from their previous estimate of ($1.51). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2022 earnings at ($0.33) EPS, Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at ($0.29) EPS, Q3 2023 earnings at ($0.31) EPS, Q4 2023 earnings at ($0.30) EPS and FY2023 earnings at ($1.18) EPS.

Several other brokerages also recently issued reports on GANX. B. Riley downgraded shares of Gain Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $11.00 to $5.00 in a research note on Friday, August 19th. BTIG Research reduced their price objective on shares of Gain Therapeutics from $30.00 to $10.00 and set a “buy” rating for the company in a research note on Sunday.

Gain Therapeutics Trading Up 0.6 %

GANX opened at $3.14 on Wednesday. The firm has a market cap of $37.31 million, a P/E ratio of -2.33 and a beta of 0.16. Gain Therapeutics has a 12 month low of $2.33 and a 12 month high of $9.50. The company has a current ratio of 5.62, a quick ratio of 5.62 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $3.32 and a 200 day moving average of $3.47.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP purchased a new stake in shares of Gain Therapeutics in the 3rd quarter valued at approximately $39,000. Jane Street Group LLC purchased a new stake in shares of Gain Therapeutics in the 1st quarter valued at approximately $48,000. Raymond James & Associates purchased a new stake in shares of Gain Therapeutics in the 3rd quarter valued at approximately $78,000. Wealth Alliance Advisory Group LLC purchased a new position in shares of Gain Therapeutics during the 3rd quarter worth approximately $82,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Gain Therapeutics during the 2nd quarter worth approximately $119,000. Institutional investors and hedge funds own 9.05% of the company’s stock.

Gain Therapeutics Company Profile

(Get Rating)

Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

See Also

Earnings History and Estimates for Gain Therapeutics (NASDAQ:GANX)

Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.